Concentra Group Holdings Parent, Inc. filings document the public reporting of a NYSE-listed occupational health services company with common stock registered under the symbol CON. Recent Form 8-K disclosures cover results of operations and financial condition, Regulation FD presentations, dividend declarations, preliminary operating metrics, and material executive and compensation matters.
The company's proxy and annual-meeting filings disclose board elections, advisory executive compensation votes, auditor ratification, stockholder voting results, and governance procedures. Other filings describe executive equity awards under the 2024 Equity Incentive Plan, leadership succession disclosures, and the company's Delaware corporate and capital-stock structure.
Concentra Group Holdings Parent, Inc. reported strong growth for Q4 and full-year 2025 and declared a cash dividend. Fourth-quarter revenue rose to $539.1 million, up 15.9% from Q4 2024, with net income increasing 58.7% to $36.2 million. Adjusted EBITDA reached $95.3 million, up 22.9%, helped by higher patient volumes and revenue per visit.
For 2025, revenue grew 13.9% to $2.16 billion and Adjusted EBITDA rose 14.6% to $431.9 million, while net income was roughly flat at $172.8 million. The company generated $197.8 million of Free Cash Flow and ended the year with a 3.4x net leverage ratio.
The board declared a quarterly cash dividend of $0.0625 per share, payable in March 2026 to stockholders of record in mid-March. For 2026, Concentra guides to revenue of $2.25–$2.35 billion, Adjusted EBITDA of $450–$470 million, Free Cash Flow of $200–$225 million, capital expenditures of $70–$80 million, and a net leverage ratio at or below 3.0x.
T. Rowe Price Associates, Inc. filed an amended Schedule 13G reporting a significant ownership stake in Concentra Group Holdings Par common stock. As of 12/31/2025, it beneficially owned 16,843,425 shares, representing 13.1% of the class, with sole voting and dispositive power over essentially all of these shares.
The filing explains that T. Rowe Price acts as an investment adviser and that its clients, not the adviser, ultimately receive dividends and sale proceeds. The T. Rowe Price Mid-Cap Value Fund holds 7,546,942 shares, or 5.9% of the class. The stake is certified as held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Concentra Group Holdings Parent, Inc. furnished an 8-K to share a press release with preliminary, unaudited results for certain operating metrics for the fourth quarter and fiscal year ended December 31, 2025. The press release is included as Exhibit 99.1.
The company also furnished an investor presentation (Exhibit 99.2) and an investor book (Exhibit 99.3) published in connection with the same press release. These materials are furnished under Items 2.02 and 7.01 of the Exchange Act and are not deemed filed or incorporated by reference into other securities filings.
Concentra Group Holdings Parent, Inc. furnished an investor presentation containing preliminary, unaudited operational metrics for the quarter ended December 31, 2025. The presentation, filed as Exhibit 99.1, will be used at the J.P. Morgan Healthcare Conference at 9:00 A.M. PT on January 14 and a recording will later be posted on the company’s investor relations website. The information is being provided under Items 2.02 and 7.01 and is designated as furnished rather than filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other Securities Act or Exchange Act filings.
Concentra Group Holdings Parent, Inc. reported an insider transaction by its Chief Executive Officer and director involving a gift of common stock. On December 17, 2025, the reporting person made a gift of 89,081 shares of common stock to the Cynthia Lee Newton Beneficiary Trust, recorded at a price of $0 per share under transaction code G.
Following the transaction, the reporting person holds 393,750 shares of common stock directly. The Form 4 also shows 89,081 shares held indirectly through the Cynthia Lee Newton Beneficiary Trust. The filing explains that the reporting person is not a trustee of the trust, does not control its investments, and therefore has no reportable pecuniary interest in the shares held by the trust.
Concentra Group Holdings Parent, Inc. executive Timothy F. Ryan reported a routine share withholding related to equity compensation. On 11/26/2025, 5,903 shares of common stock were disposed of at $21.04 per share under transaction code “F,” indicating shares were withheld to cover tax obligations from the vesting of restricted stock. After this transaction, he beneficially owned 114,097 shares of common stock directly. Ryan serves as Executive Vice President & Chief Legal Counsel, and this filing reflects administrative management of taxes on equity awards rather than an open-market sale.
Concentra Group Holdings Parent, Inc. reported an insider share disposition by one of its executives. On 11/26/2025, an officer disposed of 3,935 shares of common stock at $21.04 per share, leaving 76,163 shares beneficially owned after the transaction. The filing classifies the transaction under code F, and the explanation states that the shares were withheld to satisfy tax obligations arising from the vesting of restricted stock. The reporting person serves as Executive Vice President and Chief Operating Officer, Onsite Health & Telemedicine, and the ownership is reported as held directly.
Concentra Group Holdings Parent, Inc. reported an insider share transaction by an executive officer. On 11/26/2025, the Executive Vice President and Chief Accounting Officer had 5,903 shares of common stock withheld at a price of $21.04 per share to cover tax obligations from the vesting of restricted stock. After this tax withholding, the officer beneficially owned 114,097 shares of common stock directly.
Concentra Group Holdings Parent, Inc. reported an insider equity transaction by an executive officer. On 11/26/2025, common stock totaling 5,903 shares was disposed of at a price of $21.04 per share. The filing explains that these shares were withheld to cover tax obligations from the vesting of restricted stock, rather than an open-market sale. After this tax withholding, the reporting person beneficially owned 114,097 shares of common stock directly.